Dr. John P. Mastandrea, MD | Easton, MD ...

Dr. John P. Mastandrea

Claim this profile

University of Maryland Shore Medical Center at Easton

Studies Small Cell Lung Cancer
Studies Prostate Adenocarcinoma
5 reported clinical trials
24 drugs studied

Area of expertise

1

Small Cell Lung Cancer

John P. Mastandrea has run 2 trials for Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Prostate Adenocarcinoma

John P. Mastandrea has run 2 trials for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.

University Of Maryland Shore Medical Center At Easton

Clinical Trials John P. Mastandrea is currently running

Image of trial facility.

Stereotactic Radiosurgery vs Whole-Brain Radiotherapy

for Brain Metastasis from Lung Cancer

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

More about John P. Mastandrea

Clinical Trial Related

5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments John P. Mastandrea has experience with

  • Bicalutamide
  • Buserelin
  • Degarelix
  • Flutamide
  • Goserelin
  • Histrelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does John P. Mastandrea specialize in?

Is John P. Mastandrea currently recruiting for clinical trials?

Are there any treatments that John P. Mastandrea has studied deeply?

What is the best way to schedule an appointment with John P. Mastandrea?

What is the office address of John P. Mastandrea?

Is there any support for travel costs?